A phase 3 study among Chinese patients for an eye drug co-developed by Shanghai Henlius Biotech (HKG:2696) and Essex Bio-Technology (HKG:1061) reached the primary study endpoints, according to separate Wednesday filings with the Hong Kong bourse.
The two companies co-developed the HLX04-O injection for wet age-related macular degeneration patients.
The drug contains thee recombinant anti-vascular endothelial growth factor humanised monoclonal antibody, according to Essex's filing.
Wet age-related macular degeneration patients experience abnormal growth of blood vessels under the retina which could lead to rapid vision loss.
Shares in Essex surged nearly 11%, while that of Henlius fell 4% during late morning trading Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.